Dysport FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved April 29, 2009)
Brand name: Dysport
Generic name: abobotulinumtoxinA
Dosage form: Injection
Company: Ipsen Biopharmaceuticals, Inc.
Treatment for: Cervical Dystonia, Facial Wrinkles, Upper Limb Spasticity, Lower Limb Spasticity
Dysport (abobotulinumtoxinA) is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for:
- the treatment of cervical dystonia in adults
- the temporary improvement in the appearance of moderate to severe
glabellar lines associated with procerus and corrugator muscle
activity in adults < 65 years of age
- the treatment of spasticity in patients 2 years of age and older.
Development timeline for Dysport
Date | Article |
---|
Jul 9, 2020 | Approval Ipsen Announces Updated Indication for Dysport (abobotulinumtoxinA) for the Treatment of Spasticity in Children |
Jun 16, 2017 | Approval Ipsen Announces FDA approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults |
Aug 1, 2016 | Approval Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older |
Jul 17, 2015 | Approval Ipsen Announces FDA Approval of Dysport (abobotulinumtoxinA) for Upper Limb Spasticity |
Apr 30, 2009 | Approval FDA Approves Dysport (abobotulinumtoxinA) for Cervical Dystonia and Glabellar Lines |
Dec 29, 2008 | FDA Issues Complete Response Letter to Ipsen for Dysport Biologics License Application |
May 19, 2008 | Ipsen and Medicis Announce Acceptance of Reloxin BLA in Aesthetics by FDA |
Mar 17, 2008 | Ipsen and Medicis Announce Submission of Reloxin BLA in Aesthetics to the FDA |
Jan 31, 2008 | Ipsen: FDA Accepts for Filing a Biologics License Application (BLA)
for Dysport in Cervical Dystonia |
Dec 6, 2007 | Ipsen and Medicis Announce Submission of Reloxin in Aesthetics to the FDA |
Dec 6, 2007 | Ipsen Submits a Biologics License Application in Cervical Dystonia
to the FDA for Dysport |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer